Sign in
Taking people in South AfricaPhase 3

Tests a once-monthly pill to prevent HIV-1 in women

Tests MK-8527, a monthly pill, against daily PrEP to prevent HIV-1.

Key facts

Who runs it
Merck Sharp & Dohme LLC
Where
Bloemfontein, Cape Town, Chatsworth, Durban, East London, Edendale, Johannesburg, Johnnesburg, Khayelitsha, Ladysmith, Ndevana, Phoenix, Pietermaritzburg, Pretoria, Somkhele - Mtubatuba, and Verulam, South AfricaSee the 21 sitesAlso in 2 other countries, 9 sites
Trial code
Registry title
A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)
Status
Recruiting
Phase
Phase 3
People taking part
4,580 people, planned
Started
10 Nov 2025
Expected to end
18 Oct 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • MK-8527
  • Emtricitabine/tenofovir disoproxil (FTC/TDF)
  • Placebo matched to MK-8527
  • Placebo matched to FTC/TDF
Record updated
20 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women aged 16 to 30 who do not have HIV and have recently had vaginal sex with a cisgender man. It tests a once-monthly pill to prevent HIV-1.

Age
16 to 30 years
Sex
Women only (assigned female at birth and cisgender)
Disease stage
No HIV infection: negative HIV-1/HIV-2 test results.
Earlier treatment
Must not have ever taken cabotegravir, lenacapavir or any other long-acting HIV prevention product. Must not have had an HIV vaccine at any time, or monoclonal antibodies to HIV within 12 months before Day 1.
Biomarker or test result
Negative HIV-1/HIV-2 test results. Body weight of 35 kg (77 lb) or more.

Main reasons for not taking part

  • Allergy or other reason not to take any part of the study treatment
  • Acute or chronic hepatitis B infection
  • Cancer within 5 years of screening, except treated basal or squamous cell skin cancer or in situ cervical cancer
  • Needs any prohibited therapies from 30 days before Day 1 through the study
  • Past HIV vaccine or monoclonal antibodies to HIV within 12 months before Day 1

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • The main inclusion criteria include but are not limited to the following:
  • Is confirmed Human Immunodeficiency Virus (HIV)-uninfected based on negative HIV-1/HIV-2 test results
  • Has been sexually active (2 vaginal intercourse encounters with cisgender male individual(s) within the last 3 months)
  • Was assigned female sex at birth and is cisgender
  • Weighs ≥35 kg

Who cannot take part

  • Is receiving or is anticipated to require any prohibited therapies from 30 days prior to Day 1 through the study duration
  • Has received an HIV vaccine at any time (ie, through past participation in an investigational clinical study) or monoclonal antibodies to HIV within 12 months before Day 1
  • Has hypersensitivity or other contraindication to any component of the study interventions
  • Has evidence of acute or chronic hepatitis B infection
  • Has a history of malignancy within 5 years of screening except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer
  • Has taken cabotegravir, lenacapavir, or any other long-acting HIV prevention product at any time
  • The main exclusion criteria include but are not limited to the following:

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 16 and 30 years old?

This trial is currently available in South Africa.

Also in 2 other countries, 9 sites

  • Josha Research (Site 0045)Bloemfontein, South AfricaContact: Toll Free NumberNo longer taking part
  • Desmond Tutu Health Foundation. Philippi Village (Site 0024)Cape Town, South AfricaContact: Study CoordinatorTaking people
  • DTHF Masiphumelele Clinical Research Site (Site 0023)Cape Town, South AfricaContact: Study CoordinatorTaking people
  • SA Medical Research Council - Chatsworth Clinical Research Site (Site 0026)Chatsworth, South AfricaContact: Toll Free NumberNo longer taking part
  • Umlazi Clinical Research Site (Site 0047)Durban, South AfricaContact: Study CoordinatorTaking people
  • Wits Maternal Adolescent and Child Health Research Unit (WMRU) (Site 0027)Durban, South AfricaContact: Study CoordinatorTaking people
  • CAPRISA eThekwini Clinical Research Site (Site 0030)Durban, South AfricaContact: Toll Free NumberNo longer taking part
  • SA Medical Research Council - Botha's Hill Clinical Research Site (Site 0035)Durban, South AfricaContact: Toll Free NumberNo longer taking part
  • Synergy Biomed Research Institute (Site 0040)East London, South AfricaContact: Study CoordinatorTaking people
  • SYNAPSE Research Clinic (Site 0043)Edendale, South AfricaContact: Study CoordinatorTaking people
  • Wits RHI Ward 21 Clinical Research site (Site 0022)Johannesburg, South AfricaContact: Study CoordinatorTaking people
  • Helen Joseph Hospital-Clinical HIV Research Unit (Site 0048)Johannesburg, South AfricaContact: Toll Free NumberNo longer taking part
  • Perinatal HIV Research Unit (PHRU) (Site 0033)Johnnesburg, South AfricaContact: Study CoordinatorTaking people
  • Vuka Research Clinic (Site 0025)Khayelitsha, South AfricaContact: Toll Free NumberNo longer taking part
  • Qhakaza Mbokodo Research Clinic (Site 0028)Ladysmith, South AfricaContact: Study CoordinatorTaking people
  • Foundation For Professional Development (Site 0031)Ndevana, South AfricaContact: Toll Free NumberNo longer taking part
  • SA Medical Research Council - Phoenix Clinical Research Site (Site 0037)Phoenix, South AfricaContact: Study CoordinatorTaking people
  • CAPRISA Vulindlela Clinical Research Site (Site 0029)Pietermaritzburg, South AfricaContact: Study CoordinatorTaking people
  • Setshaba Research Centre (Site 0032)Pretoria, South AfricaContact: Study CoordinatorTaking people
  • Africa Health Research Institute (AHRI) - Mtubatuba (Site 0049)Somkhele - Mtubatuba, South AfricaContact: Toll Free NumberNo longer taking part
  • SA Medical Research Council - Verulam Clinical Research Site (Site 0036)Verulam, South AfricaContact: Study CoordinatorTaking people

About the trial

What the trial wants to find out

Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection.

Read full original descriptionShow less

The goals of this study are to learn:

* If taking MK-8527 once a month works to prevent HIV-1 infection better than a standard (usual) pre-exposure prophylaxis (PrEP) taken once a day * About the safety of MK-8527 and if people tolerate it

The 2 groups in the trial

  • MK-8527 + Placebo to FTC/TDFTreatment being tested

    Participants will receive 11 mg MK-8527 once monthly (QM) and placebo matched to Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) once daily (QD) for up to approximately 2 years. Participants will then receive open-label 200 mg FTC/245 mg TDF QD for an additional 28 days.

    Treatment: MK-8527 and Placebo matched to FTC/TDF

  • FTC/TDF + Placebo to MK-8527Existing treatment, for comparison

    Participants will receive 200 mg FTC/245 mg TDF QD and placebo matched to MK-8527 QM for up to approximately 2 years. Participants will then receive open-label 200 mg FTC/245 mg TDF QD for an additional 28 days.

    Treatment: Emtricitabine/tenofovir disoproxil (FTC/TDF) and Placebo matched to MK-8527

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis in Women
Plain-language title
Tests a once-monthly pill to prevent HIV-1 in womenGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Criteria questions
Built from NCT07071623, who can take part
Record updated
20 October 2026